Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients

BACKGROUND: CD39, a rate-limiting enzyme to convert extracellular ATP (eATP) to adenosine, has been reported to be a key modulator of immune response, but its correlation with therapeutic sensitivity remains obscure. We conducted this study to determine whether the integration of CD39 and traditiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chunnan, Liu, Zhaopei, Jin, Kaifeng, Zeng, Han, Shao, Fei, Chang, Yuan, Wang, Yiwei, Xu, Le, Wang, Zewei, Zhu, Yu, Zhang, Weijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596489/
https://www.ncbi.nlm.nih.gov/pubmed/35999267
http://dx.doi.org/10.1038/s41416-022-01943-y

Ejemplares similares

Ejemplares similares